Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Daniel Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6398-4789; OpenAlex author ID A5001654617. Sources: ClinicalTrials.gov.

Their work

Papers
11
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 3 papers, 1 trial · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1186/s13014-024-02457-y↗
  2. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1053/j.gastro.2022.02.024↗
  3. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗
  4. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  5. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Co-author DOI 10.1158/1078-0432.ccr-20-3925↗
  6. Resolving the HIF paradox in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.033↗
  7. Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Co-author DOI 10.1016/j.currproblcancer.2020.100607↗
  8. Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Co-author DOI 10.3390/cancers12092487↗
  9. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1785↗
  10. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
  11. Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism Co-author DOI 10.2139/ssrn.3188491↗

Trials 1

  1. A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Principal investigator NCT04111172↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cullen M. Taniguchi · 10 shared papers, 2018–2022 · strength 1.05
  2. Nicholas D. Nguyen · 6 shared papers, 2019–2022 · strength 0.65
  3. Ramez Kouzy · 4 shared papers, 2020–2021 · strength 0.46
  4. Joseph Abi Jaoude · 4 shared papers, 2020–2021 · strength 0.46
  5. Anirban Maitra · 5 shared papers, 2018–2022 · strength 0.45
  6. Eugene Jon Koay · 5 shared papers, 2018–2021 · strength 0.43
  7. Ethan Bernard Ludmir · 3 shared papers, 2020–2021 · strength 0.35
  8. Tara N. Fujimoto · 4 shared papers, 2018–2022 · strength 0.34
  9. Meifang Yu · 4 shared papers, 2018–2022 · strength 0.34
  10. Albert C. Koong · 3 shared papers, 2019–2021 · strength 0.28
  11. Joseph M. Herman · 3 shared papers, 2019–2021 · strength 0.28
  12. Natividad Roberto Fuentes · 2 shared papers, 2020–2022 · strength 0.26
  13. Maria E. Monberg · 2 shared papers, 2021–2022 · strength 0.23
  14. Jaewon James Lee · 2 shared papers, 2021–2022 · strength 0.23
  15. Vincent Bernard · 2 shared papers, 2021–2022 · strength 0.23
  16. Sonal Gupta · 3 shared papers, 2018–2019 · strength 0.22
  17. Carolina J. García García · 2 shared papers, 2021–2022 · strength 0.22
  18. Manoop S. Bhutani · 2 shared papers, 2021 · strength 0.21
  19. Spencer Poiset · 1 shared paper, 2024 · strength 0.18
  20. Babar Bashir · 1 shared paper, 2024 · strength 0.18
  21. Atrayee Basu Mallick · 1 shared paper, 2024 · strength 0.18
  22. Adam Christopher Mueller · 1 shared paper, 2024 · strength 0.18
  23. James A. Posey · 1 shared paper, 2024 · strength 0.18
  24. Harish Lavu · 1 shared paper, 2024 · strength 0.18
  25. Charles J. Yeo · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.